Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022

• Published in: MMWR. Morbidity and mortality weekly report Vol. 71; no. 17; pp. 606 - 608
• Main Authors: Clarke, Kristie E N, Jones, Jefferson M, Deng, Yangyang, Nycz, Elise, Lee, Adam, Iachan, Ronaldo, Gundlapalli, Adi V, Hall, Aron J, MacNeil, Adam
• Format: Journal Article Newsletter
• Language: English
• Published: United States U.S. Government Printing Office 29.04.2022; U.S. Center for Disease Control; Centers for Disease Control and Prevention
• Subjects: Age groups; Antibodies; Antibodies, Viral; Coronaviruses; COVID-19; COVID-19 vaccines; FDA approval; Full Report; Health aspects; Hospitalization; Humans; Immunization; Infections; Medical laboratories; Minority & ethnic groups; Sample size; SARS-CoV-2; Seroepidemiologic Studies; Serology; Severe acute respiratory syndrome coronavirus 2; United States - epidemiology; Vaccination; Viral antibodies; United States; United States > US
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/mmwr.mm7117e3

In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group.